BridgeBio to Seek Approval of Limb-Girdle Drug
BridgeBio intends to meet with the FDA to discuss new study data showing improvement in a marker of muscle stability, described by an executive as a
"home run".
The company's market value has nearly doubled this year due to the early launch success of Attruby, a drug for a deadly genetic heart condition.
- BridgeBio has several drugs in advanced testing, including BBP-418, an oral drug designed to boost enzyme activity involved in glycosylating the protein αDG.
Author's summary: BridgeBio seeks FDA approval for limb-girdle drug after promising study results.
More News
- 'Google Guys’ back on top: Larry Page, Sergey Brin grow $50 billion richer, close in on Larry Ellison’s lead - Trending News | The Financial Express
- 2 US Navy aircraft crash in South China Sea
- West Indies ease past Bangladesh in first T20I
- READY, FIRE, AIM: Fly Me to the Moon – Pagosa Daily Post News Events & Video for Pagosa Springs Colorado
- Extinction rates have slowed across many plant and animal groups, study shows
- Biofuels and ethanol key to the future of U.S. agriculture - High Plains Journal
- Why Hiring a Fishers Personal Injury Lawyer Is Key After a Car Accident, Slip, or Dog Bite | NorthPennNow
- Giving States Waivers From Accountability Is a Dangerous Step Backward for Kids
- MMJ BioPharma Cultivation: EXPOSÉ: DEA's Marijuana Licensing Scheme Exposed - MMJ BioPharma's Case Reveals DEA Contradiction Blocking FDA Approved Cannabis Medicine
- Why Experienced Lawyers Matter in a Personal Injury Case | NorthPennNow